Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18824576 | DIFFERENTIATION OF PANCREATIC ENDOCRINE CELLS | September 2024 | June 2025 | Allow | 9 | 3 | 0 | Yes | No |
| 18824588 | DIFFERENTIATION OF PANCREATIC ENDOCRINE CELLS | September 2024 | December 2024 | Allow | 4 | 2 | 0 | No | No |
| 18629423 | ENGINEERED IMMUNE CELLS WITH RECEPTOR CROSS-TALK | April 2024 | September 2025 | Allow | 18 | 2 | 0 | No | No |
| 18411647 | TRANSGENE CASSETTES DESIGNED TO EXPRESS A HUMAN MECP2 GENE | January 2024 | March 2025 | Allow | 14 | 1 | 0 | No | No |
| 18391799 | DIFFERENTIATION OF PANCREATIC ENDOCRINE CELLS | December 2023 | April 2024 | Allow | 4 | 1 | 0 | No | No |
| 18382284 | COMPOSITIONS AND METHODS FOR TREATING CANCER | October 2023 | January 2025 | Allow | 15 | 2 | 0 | Yes | No |
| 18361233 | CELL CULTURE MEDIUM | July 2023 | May 2025 | Abandon | 22 | 2 | 0 | Yes | No |
| 18007709 | TREATMENT OF CD30-POSITIVE CANCER | December 2022 | March 2026 | Allow | 39 | 2 | 0 | Yes | No |
| 17988257 | DIFFERENTIATION OF PANCREATIC ENDOCRINE CELLS | November 2022 | September 2023 | Allow | 10 | 1 | 0 | Yes | No |
| 17925411 | Single Domain Antibodies and Their Use in Cancer Therapies | November 2022 | December 2025 | Allow | 37 | 1 | 0 | Yes | No |
| 17917770 | ENHANCED VIRAL TRANSDUCTION OF MAMMALIAN CELLS USING MATERIAL SCAFFOLDS | October 2022 | February 2026 | Allow | 40 | 1 | 0 | Yes | No |
| 17863832 | MEDIUM HAVING REDUCED OSMOTIC PRESSURE | July 2022 | September 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17732581 | ANTI-ROBO1 CAR-T CELL, AND PREPARATION AND APPLICATION THEREOF | April 2022 | January 2026 | Abandon | 45 | 1 | 0 | No | No |
| 17726517 | Modulation of Engineered Immune Cell Receptor Translation Using Noncoding Sequence Elements | April 2022 | January 2026 | Abandon | 45 | 1 | 0 | No | No |
| 17767806 | ENGINEERED IMMUNE CELL | April 2022 | December 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17763663 | ROR1 specific chimeric antigen receptors and their therapeutic applications | March 2022 | August 2025 | Allow | 41 | 1 | 0 | Yes | No |
| 17761723 | IMMUNE EFFECTOR CELL IN WHICH EXPRESSION IS REGULATED BY CYTOKINES | March 2022 | November 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17761791 | GENETICALLY MODIFIED NK CELL LINE TRANSDUCED WITH GENE ENCODING NOVEL CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF | March 2022 | October 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17641404 | COMPOSITIONS AND METHODS FOR USE IN IMMUNOTHERAPY | March 2022 | December 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17649305 | KNOCKDOWN OR KNOCKOUT OF ONE OR MORE OF TAP2, NLRC5, B2m, TRAC, RFX5, RFXAP and RFXANK TO MITIGATE T CELL RECOGNITION OF ALLOGENEIC CELL PRODUCTS | January 2022 | January 2026 | Allow | 48 | 3 | 1 | Yes | Yes |
| 17626768 | ENHANCED IMMUNE CELLS USING DUAL SHRNA AND COMPOSITION INCLUDING THE SAME | January 2022 | February 2026 | Abandon | 49 | 2 | 0 | No | No |
| 17572070 | Compositions and Methods for Treating Cancer with Anti-CD19/CD22 Immunotherapy | January 2022 | April 2025 | Allow | 39 | 1 | 0 | No | No |
| 17559985 | TREATMENT OF LIVER FAILURE BY EX VIVO REPROGRAMMED IMMUNE CELLS | December 2021 | September 2024 | Abandon | 32 | 1 | 1 | No | No |
| 17555581 | COMPOSITIONS AND METHODS FOR MAKING SENSORY NEURONS | December 2021 | June 2024 | Allow | 30 | 2 | 0 | No | No |
| 17620942 | T CELL RECEPTORS RECOGNIZING R175H OR Y220C MUTATION IN P53 | December 2021 | August 2025 | Allow | 43 | 1 | 1 | No | No |
| 17553516 | METHOD FOR THE GENERATION OF A TRIVALENT ANTIBODY EXPRESSING CELL BY TARGETED INTEGRATION OF MULTIPLE EXPRESSION CASSETTES IN A DEFINED ORGANIZATION | December 2021 | February 2026 | Abandon | 50 | 1 | 1 | No | No |
| 17540777 | METHOD FOR LONG-TERM EX VIVO MAINTENANCE OR EXPANSION OF HUMAN ERYTHROBLAST, HUMAN MEGAKARYOCYTE-ERYTHROID PROGENITOR, OR HUMAN COMMON MYELOID PROGENITOR CELL AND APPLICATION THEREOF | December 2021 | January 2024 | Allow | 25 | 1 | 0 | No | No |
| 17525525 | GENETICALLY MODIFIED NATURAL KILLER CELLS AND METHODS OF USE THEREOF | November 2021 | June 2025 | Abandon | 43 | 2 | 1 | No | Yes |
| 17610083 | LOCKR-MEDIATED RECRUITMENT OF CAR T CELLS | November 2021 | September 2025 | Abandon | 46 | 1 | 0 | No | No |
| 17608587 | RESIN FILM FORMED BY SCAFFOLD MATERIAL FOR CELL CULTURE AND CONTAINER FOR CELL CULTURE | November 2021 | October 2024 | Allow | 35 | 0 | 0 | No | No |
| 17607833 | CELLS EXPRESSING A CHIMERIC RECEPTOR FROM A MODIFIED CD247 LOCUS, RELATED POLYNUCLEOTIDES AND METHODS | October 2021 | May 2025 | Allow | 43 | 1 | 0 | Yes | No |
| 17606756 | PREPARATION OF HUMAN ALLOGENEIC LIVER-DERIVED PROGENITOR CELLS | October 2021 | May 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17604954 | COMPOSITIONS AND METHODS FOR INCREASING MEGAKARYOCYTE PRODUCTION | October 2021 | April 2025 | Allow | 42 | 2 | 0 | No | No |
| 17599831 | Treatment Of Intervertebral Disc Degeneration | September 2021 | February 2026 | Allow | 53 | 2 | 0 | Yes | No |
| 17480466 | ENGINEERED IMMUNE CELLS WITH RECEPTOR CROSS-TALK | September 2021 | January 2024 | Allow | 27 | 2 | 0 | Yes | No |
| 17472424 | METHODS FOR ENHANCING DIRECT REPROGRAMMING OF CELLS | September 2021 | November 2023 | Abandon | 26 | 1 | 0 | No | No |
| 17446563 | ALIGNMENT OF CELLS IN ENGINEERED TISSUES | August 2021 | January 2024 | Allow | 28 | 2 | 0 | Yes | Yes |
| 17432380 | EXPANSION OF NATURAL KILLER AND CHIMERIC ANTIGEN RECEPTOR-MODIFIED CELLS | August 2021 | June 2025 | Allow | 46 | 2 | 0 | No | No |
| 17430676 | MODIFIED IMMUNE CELLS HAVING ADENOSINE DEAMINASE BASE EDITORS FOR MODIFYING A NUCLEOBASE IN A TARGET SEQUENCE | August 2021 | November 2025 | Allow | 52 | 1 | 1 | Yes | No |
| 17429201 | METHODS FOR PREPARING EXTRACELLULAR VESICLES (EV) DEPLETEMEDIA | August 2021 | March 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17392641 | Novel Animal Model For Laing Distal Myopathy (Mpd1) And Methods of Use Thereof | August 2021 | October 2023 | Abandon | 26 | 1 | 0 | No | No |
| 17390839 | DIFFERENTIATION OF PANCREATIC ENDOCRINE CELLS | July 2021 | November 2023 | Allow | 27 | 1 | 1 | Yes | No |
| 17422885 | Targeted Nuclear RNA Cleavage and Polyadenylation with CRISPR-Cas | July 2021 | March 2025 | Allow | 44 | 1 | 1 | No | No |
| 17358760 | PSORIASIS AND OTHER AUTOIMMUNE DISEASES ANTIGEN IMMUNE MODULATOR (AIM) THERAPEUTIC PLATFORM | June 2021 | September 2024 | Abandon | 39 | 2 | 0 | No | No |
| 17345885 | Enhancement of Mesenchymal Stem Cell Anti-inflammatory and Regenerative Activity Using mTOR Inhibitors | June 2021 | February 2024 | Abandon | 32 | 2 | 0 | No | No |
| 17312259 | COMBINATION THERAPY FOR TREATING MUSCULAR DYSTROPHY | June 2021 | February 2026 | Abandon | 56 | 3 | 0 | No | No |
| 17295256 | GENETICALLY MODIFIED ANIMAL WITH CANINE OR CHIMERIC PD-1 | May 2021 | February 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17294913 | COMPOSITION FOR RECONSTITUTING HUMAN SKIN TISSUE HAVING HAIR FOLLICLES, HUMAN SKIN TISSUE MODEL ANIMAL, AND PRODUCTION METHOD THEREOF | May 2021 | March 2025 | Abandon | 46 | 1 | 1 | No | No |
| 17293415 | TRANSGENIC BETTA | May 2021 | July 2024 | Allow | 38 | 2 | 0 | Yes | No |
| 17307235 | COMPOSITIONS AND METHODS FOR TREATING CANCER | May 2021 | July 2023 | Allow | 26 | 1 | 1 | No | No |
| 17309154 | RECOMBINANT PARVOVIRAL VECTORS AND METHOD OF MAKING AND USE THEREOF | April 2021 | January 2025 | Allow | 45 | 1 | 1 | No | No |
| 17231328 | ACTIVATION OF YAP SIGNALING FOR SENSORY RECEPTOR REGENERATION | April 2021 | March 2024 | Abandon | 35 | 2 | 0 | Yes | No |
| 17285084 | Chimeric antigen receptor carrying truncated or untruncated myeloid cell triggering receptor signaling structure and applications thereof | April 2021 | April 2025 | Abandon | 48 | 2 | 0 | No | No |
| 17301637 | PROCESS TO PRODUCE KLOTHO PROTEIN IN VITRO | April 2021 | October 2023 | Allow | 30 | 2 | 0 | Yes | No |
| 17213611 | MODIFIED MAMMALIAN CELLS | March 2021 | February 2024 | Allow | 34 | 1 | 1 | No | No |
| 17209268 | USE OF MEMORY LYMPHOCYTE POPULATION IN LIVER CANCER TREATMENT | March 2021 | December 2025 | Abandon | 57 | 3 | 1 | No | No |
| 17204072 | METHODS FOR VIRAL INACTIVATION OF HUMAN PLATELET LYSATE | March 2021 | December 2025 | Abandon | 57 | 5 | 0 | No | No |
| 17275983 | TRANSPLANTATION OF MITOCHONDRIA INTO LYMPHOID ORGAN AND COMPOSITION THEREFOR | March 2021 | December 2024 | Allow | 45 | 2 | 0 | Yes | No |
| 17195288 | AAV-MEDIATED SUBCELLULAR TARGETING OF HETEROLOGOUS RHODOPSINS IN RETINAL GANGLION CELLS | March 2021 | January 2025 | Allow | 46 | 1 | 0 | Yes | No |
| 16974427 | Tunable, simple, higher-yield, higher-rate, lower-cost recovery method of biopharmaceutical products from cell factories | February 2021 | June 2023 | Abandon | 29 | 3 | 0 | No | No |
| 17144800 | Modified Cell Expressing Therapeutic Agent and Uses thereof | January 2021 | March 2024 | Abandon | 38 | 1 | 1 | No | No |
| 17254472 | TARGETING OF MULTIPLE ANTIGENS WITH MULTIPLEX CAR T CELLS IN SOLID AND LIQUID MALIGNANCIES | December 2020 | July 2025 | Allow | 55 | 2 | 1 | No | No |
| 17112299 | TRANSGENE CASSETTES DESIGNED TO EXPRESS A HUMAN MECP2 GENE | December 2020 | September 2023 | Allow | 34 | 1 | 1 | No | No |
| 17112911 | CONDITIONED MEDIUM FROM CELLS CULTURED UNDER HYPOXIC CONDITIONS AND USES THEREOF | December 2020 | May 2024 | Allow | 41 | 2 | 1 | No | No |
| 17108009 | Methods and materials for rapid preparation of 3D spheroids/organoids | December 2020 | March 2023 | Allow | 28 | 1 | 0 | Yes | No |
| 17054939 | Method Of Reinforcing Efficacy Of Stem Cells Using Ethionamide | November 2020 | February 2024 | Allow | 39 | 2 | 0 | Yes | No |
| 17049728 | METHOD FOR PRODUCING PRIMITIVE GUT TUBE CELLS | October 2020 | November 2024 | Abandon | 48 | 2 | 0 | No | No |
| 17049018 | METHOD FOR DIFFERENTIATION OF OCULAR CELLS AND USE THEREOF | October 2020 | February 2024 | Allow | 39 | 1 | 0 | Yes | No |
| 17048021 | COMPOSITIONS AND METHODS FOR MULTIPLEXED TUMOR VACCINATION WITH ENDOGENOUS GENE ACTIVATION | October 2020 | August 2025 | Allow | 58 | 3 | 1 | Yes | No |
| 17065814 | EGFR BINDING MOIETY-PRESENTING BACTERIOPHAGES FOR TUMOUR TREATMENT | October 2020 | November 2023 | Abandon | 38 | 1 | 1 | No | No |
| 16766836 | PLASMID DNA ENCODING BETA-ENDORPHIN, BACTERIAL PRODUCER, ANALGESIC AGENT | October 2020 | July 2024 | Abandon | 50 | 1 | 0 | Yes | No |
| 17044232 | RESCUING VOLTAGE-GATED SODIUM CHANNEL FUNCTION IN INHIBITORY NEURONS | September 2020 | June 2024 | Allow | 45 | 1 | 0 | Yes | No |
| 17042349 | USE OF HOLLOW FIBERS TO OBTAIN BLOOD OR A BLOOD DERIVATIVE IMPOVERISHED FROM BLOOD CELLS AND PLATELETS DERIVED EXTRACELLULAR VESICLES | September 2020 | April 2024 | Allow | 42 | 3 | 0 | Yes | No |
| 17021771 | DEVICE AND USES THEREOF FOR TREATING DIABETES | September 2020 | July 2023 | Allow | 34 | 2 | 0 | No | No |
| 17012957 | GENETICALLY ENGINEERED T CELLS HAVING IMPROVED PERSISTENCE IN CULTURE | September 2020 | February 2025 | Allow | 54 | 5 | 1 | Yes | No |
| 17001817 | THREE-DIMENSIONAL CELL SPHEROID WITH HIGH PROLIFERATION ACTIVITY, AND PRODUCING METHOD AND USE THEREFOR | August 2020 | December 2025 | Abandon | 60 | 5 | 0 | No | No |
| 16975364 | COMBINATION CANCER THERAPY WITH ANTI-CANCER AGENTS AND ANTIBODIES TARGETING A COMPLEX COMPRISING NON-CLASSICAL HLA-I AND NEOANTIGEN | August 2020 | June 2024 | Abandon | 46 | 1 | 0 | No | No |
| 16965395 | CELL INDUCTION METHOD | July 2020 | August 2024 | Allow | 49 | 2 | 1 | Yes | No |
| 16963095 | SYNNOTCH RECEPTOR-REGULATED EXPRESSION OF IL12 | July 2020 | March 2024 | Abandon | 43 | 1 | 0 | No | No |
| 16961773 | LYMPHOCYTE PRODUCTION METHOD | July 2020 | March 2024 | Allow | 44 | 3 | 0 | Yes | No |
| 16961483 | GENETICALLY ENGINEERED HEMATOPOIETIC STEM CELL AS A PLATFORM FOR SYSTEMIC PROTEIN EXPRESSION | July 2020 | February 2024 | Allow | 43 | 3 | 1 | No | No |
| 16958485 | CELL AGGREGATION SUPPRESSOR | June 2020 | July 2025 | Abandon | 60 | 3 | 1 | Yes | No |
| 16957918 | Compositions and Methods for Producing Megakaryocytes | June 2020 | June 2024 | Allow | 47 | 2 | 1 | Yes | No |
| 16909283 | MATERIALS AND METHODS FOR TREATMENT OF HEMOGLOBINOPATHIES | June 2020 | January 2024 | Allow | 42 | 2 | 0 | Yes | No |
| 16957086 | GENERATION OF INDUCED PLURIPOTENT CELLS BY CRISPR ACTIVATION | June 2020 | July 2024 | Allow | 48 | 3 | 1 | No | No |
| 16906937 | METHOD FOR THE GENERATION OF A MULTIVALENT, MULTISPECIFIC ANTIBODY EXPRESSING CELLS BY TARGETED INTEGRATION OF MULTIPLE EXPRESSION CASSETTES IN A DEFINED ORGANIZATION | June 2020 | April 2024 | Allow | 46 | 4 | 0 | No | No |
| 16770663 | INSERTABLE CULTURE CONTAINER AND KIT FOR THREE-DIMENSIONAL CELL CULTURE, AND THREE-DIMENSIONAL CELL CO-CULTURE METHOD USING SAME | June 2020 | February 2023 | Allow | 33 | 1 | 0 | Yes | No |
| 16769926 | CRISPR-CAS9 MODIFIED CD34+ HUMAN HEMATOPOIETIC STEM AND PROGENITOR CELLS AND USES THEREOF | June 2020 | July 2024 | Allow | 50 | 3 | 1 | No | No |
| 16893306 | METHODS FOR ATTENUATING VIRAL INFECTION AND FOR TREATING LUNG INJURY | June 2020 | May 2024 | Allow | 48 | 2 | 2 | Yes | No |
| 16764866 | SYSTEM AND METHOD FOR CARBON MONOXIDE ATMOSPHERE STORED BLOOD COMPONENTS | May 2020 | April 2024 | Abandon | 47 | 0 | 1 | No | No |
| 16763834 | METHODS AND COMPOSITIONS FOR TREATING CANCER BY TARGETING THE CLEC2D-KLRB1 PATHWAY | May 2020 | February 2024 | Allow | 45 | 2 | 1 | Yes | No |
| 16760004 | METHOD FOR IMPROVING STEM CELL MIGRATION USING ETHIONAMIDE | April 2020 | December 2023 | Allow | 44 | 4 | 0 | Yes | No |
| 16615828 | System for DNA editing and uses thereof | April 2020 | November 2024 | Abandon | 59 | 2 | 0 | No | No |
| 16648414 | CELL CULTURE MEDIUM | March 2020 | December 2023 | Abandon | 45 | 2 | 1 | No | No |
| 16806013 | CELL STRAIN FOR REDUCING PRODUCTION OF REPLICATION COMPETENT ADENOVIRUS, AND CONSTRUCTION METHOD AND USE THEREOF | March 2020 | June 2023 | Allow | 40 | 1 | 1 | Yes | No |
| 16631781 | COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES | January 2020 | March 2024 | Allow | 50 | 2 | 1 | No | No |
| 16629477 | METHOD FOR MANAGING PAIN | January 2020 | October 2023 | Allow | 45 | 2 | 1 | No | No |
| 16617429 | METHOD FOR THE ISOLATION OF SUBPOPULATIONS OF CARDIAC PROGENITOR CELLS AND RELATED USES IN THE MEDICAL FIELD | November 2019 | February 2024 | Allow | 51 | 3 | 0 | Yes | No |
| 16578026 | FUNCTIONALIZED WELL PLATE, METHODS OF PREPARATION AND USE THEREOF | September 2019 | January 2024 | Allow | 60 | 2 | 1 | Yes | No |
| 16576601 | WNT-ACTIVATED ADIPOSE-DERIVED STEM CELL APPARATUSES, METHODS AND SYSTEMS | September 2019 | December 2025 | Allow | 60 | 4 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SPENCE, JENNIFER SUZANNE.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 50.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner SPENCE, JENNIFER SUZANNE works in Art Unit 1633 and has examined 86 patent applications in our dataset. With an allowance rate of 65.1%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 45 months.
Examiner SPENCE, JENNIFER SUZANNE's allowance rate of 65.1% places them in the 26% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by SPENCE, JENNIFER SUZANNE receive 2.21 office actions before reaching final disposition. This places the examiner in the 61% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by SPENCE, JENNIFER SUZANNE is 45 months. This places the examiner in the 12% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +47.0% benefit to allowance rate for applications examined by SPENCE, JENNIFER SUZANNE. This interview benefit is in the 91% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 30.8% of applications are subsequently allowed. This success rate is in the 62% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 39.1% of cases where such amendments are filed. This entry rate is in the 59% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 92% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 126.3% are granted (fully or in part). This grant rate is in the 96% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.